- NCIt
- C8101
Loading cancer entity…
Loading cancer entity…
Clinical trials
1,164 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06098651 | A Study of DCR-STAT3 in Adults With Solid Tumors | completed | Phase 1 | 26 | Dicerna Pharmaceuticals, Inc., a Novo Nordisk companyINDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT04221204 | A Monotherapy in Subjects With Advanced Solid Tumors | completed | Phase 1 | 23 | 3D Medicines (Beijing) Co., Ltd.INDUSTRY | 2 | Sep 22, 2026 | clinicaltrials |
| NCT05230186 |
| A Tissue Collection Study in Patients Who Respond to Immune Checkpoint Inhibitors to Identify Targets of Tumor-Reactive T Cells. |
| completed |
| — |
| 12 |
| TScan Therapeutics, Inc.INDUSTRY |
| 1 |
| Sep 15, 2026 |
| clinicaltrials |
| NCT05864144 | A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 98 | Sensei Biotherapeutics, Inc.INDUSTRY | 1 | Sep 2, 2026 | clinicaltrials |
| NCT04902872 | Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 69 | Cybrexa TherapeuticsINDUSTRY | 1 | Aug 20, 2026 | clinicaltrials |
| NCT06059547 | Neoadjuvant Immunotherapy Combined With the Anti-GDF-15 Antibody Visugromab to Treat Muscle Invasive Bladder Cancer | completed | Phase 2 | 31 | CatalYm GmbHINDUSTRY | 1 | Aug 19, 2026 | clinicaltrials |
| NCT03656172 | Interest of Reticulocyte Haemoglobin Content (RET-he) in Management of Functional Anemia for Patient With Solid Tumor(RET-HE) | completed | — | 51 | Institut Cancerologie de l'OuestOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT06614140 | Personalized Neoantigen Cancer Vaccine for Patients With Solid Tumors | completed | Phase 1 / Phase 2 | 8 | Seqker Biosciences, Inc.INDUSTRY | 1 | Jul 24, 2026 | clinicaltrials |
| NCT06403436 | A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects With Advanced Solid Tumors(TT-CSP-001) | completed | Phase 1 | 45 | TOLREMO therapeutics AGINDUSTRY | 3 | Jul 7, 2026 | clinicaltrials |
| NCT02088775 | PET-CT in Determining the Radioembolization Dose Delivered to Patients With Liver Metastasis, Primary Liver Cancer, or Biliary Cancer | completed | N/A | 44 | Fox Chase Cancer CenterOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT05763004 | A Clinical Study to Evaluate the Safety, Tolerability and Efficacy of IOS-1002 Administered Alone and in Combination With Pembrolizumab, a PD-1 Monoclonal Antibody in Advanced Solid Tumors | completed | Phase 1 | 47 | ImmunOs Therapeutics AGINDUSTRY | 1 | Jun 26, 2026 | clinicaltrials |
| NCT05620472 | Molecular Imaging of EpCAM Receptors Using [99mTc]Tc(CO)3-(HE)3-Ec1 | completed | Phase 1 | 10 | Tomsk National Research Medical Center of the Russian Academy of SciencesOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT04552288 | Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies | completed | Phase 2 | 51 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT01705548 | Hypofractionated Stereotactic Radiosurgery in Treating Patients With Large Brain Metastasis | completed | N/A | 24 | Emory UniversityOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT05865990 | HER3-DXd in Breast Cancer and NSCLC Brain Metastases and Solid Tumor Leptomeningeal Disease(TUXEDO-3) | completed | Phase 2 | 63 | MedSIROTHER | 2 | May 4, 2026 | clinicaltrials |
| NCT04143711 | Study of DF1001 in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 270 | Dragonfly TherapeuticsINDUSTRY | 6 | Mar 18, 2026 | clinicaltrials |
| NCT06108479 | Study of DF6215 in Patients With Advanced Solid Tumors | completed | Phase 1 | 35 | Dragonfly TherapeuticsINDUSTRY | 3 | Mar 18, 2026 | clinicaltrials |
| NCT04705818 | Combining Epigenetic And Immune Therapy to Beat Cancer.(CAIRE) | completed | Phase 2 | 164 | Institut BergoniéOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT00343460 | APF530 or Aloxi (Palonosetron Hydrochloride) Combined With Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer | completed | Phase 3 | 1,428 | Heron TherapeuticsINDUSTRY | 1 | Mar 2, 2026 | clinicaltrials |
| NCT03445858 | Pembrolizumab in Combination With Decitabine and Hypofractionated Index Lesion Radiation in Pediatrics and Young Adults | completed | Early Phase 1 | 22 | Children's Hospital Medical Center, CincinnatiOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT04504942 | Basket Study of Leronlimab (PRO 140) in Patients With CCR5+ Locally Advanced or Metastatic Solid Tumors | completed | Phase 2 | 16 | CytoDyn, Inc.INDUSTRY | 1 | Jan 23, 2026 | clinicaltrials |
| NCT05276284 | Thiopurine Enhanced Mutations for PD-1/Ligand-1 Efficacy(TEMPLE) | completed | Phase 1 / Phase 2 | 18 | Kristoffer RohrbergOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT04587479 | A First-in-Human Study of JAB-8263 in Adult Patients With Advanced Solid Tumors | completed | Phase 1 | 41 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jan 13, 2026 | clinicaltrials |
| NCT03905148 | Study of the Safety and Pharmacokinetics of BGB-283 (Lifirafenib) and PD-0325901 (Mirdametinib) in Participants With Advanced or Refractory Solid Tumors | completed | Phase 1 | 91 | BeiGeneINDUSTRY | 2 | Jan 7, 2026 | clinicaltrials |
| NCT03573310 | A Study of JNJ-64619178, an Inhibitor of PRMT5 in Participants With Advanced Solid Tumors, NHL, and Lower Risk MDS | completed | Phase 1 | 114 | Janssen Research & Development, LLCINDUSTRY | 5 | Dec 18, 2025 | clinicaltrials |
| NCT05586321 | Study of Safety and Antitumor Activity of GEN1056 in Participants With Advanced Solid Tumors | completed | Phase 1 | 26 | GenmabINDUSTRY | 3 | Nov 24, 2025 | clinicaltrials |
| NCT05597839 | Study of DF9001 in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 24 | Dragonfly TherapeuticsINDUSTRY | 1 | Oct 29, 2025 | clinicaltrials |
| NCT05723640 | The Safety and Dosimetry Study of 177Lu-LNC1004 Injection | completed | Phase 1 | 11 | Yantai LNC Biotechnology Singapore PTE. LTD.INDUSTRY | 1 | Sep 8, 2025 | clinicaltrials |
| NCT05114668 | Safety, Tolerability, and Pharmacokinetics of EVT801 in Patients With Advanced Solid Tumours | completed | Phase 1 | 32 | Kazia Therapeutics LimitedINDUSTRY | 1 | Sep 2, 2025 | clinicaltrials |
| NCT00712712 | Morphine After Radiofrequency Ablation of Painful Bone Metastases in Patients With Cancer(MEDOR) | completed | Phase 2 | 78 | Institut BergoniéOTHER | 1 | Aug 29, 2025 | clinicaltrials |
| NCT04169321 | Granzyme B PET Imaging Drug as a Predictor of Immunotherapy Response to Checkpoint Inhibitors | completed | Phase 1 | 13 | Cytosite Biopharma Inc.INDUSTRY | 2 | Aug 22, 2025 | clinicaltrials |
| NCT03084757 | SHIVA02 - Evaluation of the Efficacy of Targeted Therapy Based on Tumor Molecular Profiling in Patients With Advanced Cancer Using Each Patient as Its Own Control (SHIVA02)(SHIVA02) | completed | N/A | 170 | Institut CurieOTHER | 1 | Aug 11, 2025 | clinicaltrials |
| NCT02220556 | Evaluation of Different Analysis Methods for Circulating Tumor Cells, Circulating Endothelial Cell, and Circulating Tumor DNA in Patient Followed for a Tumoral Pathology(CTC-CEC-ADN) | completed | N/A | 360 | Institut CurieOTHER | 1 | Aug 8, 2025 | clinicaltrials |
| NCT03410121 | Comparison of Humeral or Thoracic Implantation of an Central Veinous Access by an Implantable Venous Access Device in Patients With Solid Tumors Requiring Chemotherapy(PACPAC-EPOC) | completed | N/A | 361 | Center Eugene MarquisOTHER | 1 | Aug 5, 2025 | clinicaltrials |
| NCT02775292 | Gene-Modified T Cells, Vaccine Therapy, and Nivolumab in Treating Patients With Stage IV or Locally Advanced Solid Tumors Expressing NY-ESO-1(NYM) | completed | Phase 1 | 1 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 30, 2025 | clinicaltrials |
| NCT04306900 | TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers | completed | Phase 1 | 185 | Trishula Therapeutics, Inc.INDUSTRY | 2 | Jul 29, 2025 | clinicaltrials |
| NCT03520075 | Study of ASTX029 in Subjects With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 192 | Taiho Oncology, Inc.INDUSTRY | 4 | Jul 3, 2025 | clinicaltrials |
| NCT00540982 | Vinorelbine in Treating Patients With Advanced Solid Tumors That Have Not Responded to Treatment and Liver Dysfunction | completed | Phase 1 / Phase 2 | 47 | City of Hope Medical CenterOTHER | 1 | Jul 2, 2025 | clinicaltrials |
| NCT03990233 | A Trial of BI 765063 Monotherapy and in Combination With BI 754091 in Patients With Advanced Solid Tumours | completed | Phase 1 | 100 | OSE ImmunotherapeuticsINDUSTRY | 2 | Jun 26, 2025 | clinicaltrials |
| NCT04899505 | Evaluation of the Impact of Chemotherapy on Body Odor in Adolescents and Young Adults in Oncology(ODORAJA) | completed | — | 27 | Institut CurieOTHER | 1 | May 16, 2025 | clinicaltrials |
| NCT05759949 | First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors | completed | Phase 1 | 41 | Relay Therapeutics, Inc.INDUSTRY | 1 | May 16, 2025 | clinicaltrials |
| NCT02153151 | Measuring Biomarker Response to AMP-514 in Blood Samples From Patients With Solid Tumors Undergoing Radiotherapy | completed | — | 21 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 2, 2025 | clinicaltrials |
| NCT00638898 | Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor | completed | Phase 1 | 25 | City of Hope Medical CenterOTHER | 1 | Mar 20, 2025 | clinicaltrials |
| NCT04761198 | A Study of Etigilimab and Nivolumab in Participants With Locally Advanced or Metastatic Tumors | completed | Phase 1 / Phase 2 | 76 | Mereo BioPharmaINDUSTRY | 2 | Mar 17, 2025 | clinicaltrials |
| NCT04597541 | A Study of AK112 for Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 59 | AkesoINDUSTRY | 1 | Mar 10, 2025 | clinicaltrials |
| NCT03761017 | MGD019 DART® Protein in Unresectable/Metastatic Cancer | completed | Phase 1 | 162 | MacroGenicsINDUSTRY | 5 | Mar 6, 2025 | clinicaltrials |
| NCT04105335 | A Study of MTL-CEBPA in Combination With a PD-1 Inhibitor in Patients With Advanced Solid Tumours (TIMEPOINT)(TIMEPOINT) | completed | Phase 1 | 50 | Mina Alpha LimitedINDUSTRY | 1 | Mar 6, 2025 | clinicaltrials |
| NCT01586104 | Intensity-Modulated Radiation Therapy in Treating Younger Patients With Lung Metastases | completed | N/A | 20 | Ann & Robert H Lurie Children's Hospital of ChicagoOTHER | 1 | Feb 10, 2025 | clinicaltrials |
| NCT03441100 | TCR-engineered T Cells in Solid Tumors: IMA202-101(ACTengine) | completed | Phase 1 | 16 | Immatics US, Inc.INDUSTRY | 2 | Feb 4, 2025 | clinicaltrials |
| NCT03628677 | A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies | completed | Phase 1 | 75 | Arcus Biosciences, Inc.INDUSTRY | 2 | Feb 4, 2025 | clinicaltrials |
Data updated 21 hours agoSource updated Sep 29, 2026source: clinicaltrials